Eli Lilly stands at a pivotal moment in pharmaceutical history, with its obesity and diabetes treatments reshaping both healthcare and its financial trajectory.
Following exceptional Q3 2025 earnings and a landmark government pricing agreement announced just today, the Indianapolis-based giant presents a compelling investment case, though not without considerations.
Recommendation: Strong Buy with awareness of valuation metrics and execution risks.
Recent Financial Performance: Exceptional Growth
Eli Lilly delivered stunning third-quarter 2025 results, with revenue surging 54% year-over-year to $17.60 billion, crushing analyst expectations of $16.01 billion.
Adjusted earnings per share reached $7.02, significantly exceeding the $5.69 consensus estimate.
The pharmaceutical giant’s performance was driven predominantly by its GLP-1 portfolio. Zepbound prescriptions in the U.S. tripled year-over-year in the third quarter, and the drug now accounts for 63% of branded weight loss drug prescriptions in the U.S.
Meanwhile, Mounjaro’s total U.S. prescriptions rose by over 60%, capturing a 45% market share in the type 2 diabetes incretin analog market.
This exceptional performance prompted management to raise full-year guidance substantially.
The company now expects fiscal 2025 revenue between $63 billion and $63.5 billion, up from previous guidance of $60 to $62 billion, with adjusted profit expected between $23 and $23.70 per share.
Game-Changing Trump Administration Deal
In a development that could fundamentally alter the obesity drug market, President Trump announced deals with Eli Lilly and Novo Nordisk to slash prices of obesity drugs, with certain Medicare patients paying a copay of just $50 per month for all approved uses of injectable and oral GLP-1 drugs.
Starting doses of upcoming obesity pills will be $145 per month for everyone getting them through Medicare, Medicaid or TrumpRx.
This agreement represents both opportunity and complexity. Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them.
While lower prices might seem concerning, the dramatic expansion in accessible patient population could more than compensate through volume growth.
The timing is particularly strategic as Eli Lilly’s pill orforglipron could launch next year, offering a convenient oral alternative that addresses one of the key barriers to GLP-1 adoption.
Pipeline Momentum and Growth Drivers
Beyond the GLP-1 franchise, Lilly demonstrated robust pipeline progress. The company advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and achieved U.S. FDA approval of Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer.
The company’s manufacturing expansion underscores confidence in sustained demand. Lilly announced new facilities in Virginia and Texas and the expansion of its existing Puerto Rico site, addressing supply constraints that have occasionally limited growth potential.
International expansion is accelerating rapidly. CEO David Ricks highlighted “really strong international performance,” pointing to Mounjaro’s launch in China, Brazil and India earlier this year, noting that “what we’re seeing is a global demand for this product.”
Analyst Consensus and Valuation
Wall Street maintains overwhelming bullish sentiment on Lilly. The 14 analysts that cover Eli Lilly stock have a consensus rating of “Strong Buy” and an average price target of $967.43, which forecasts a 3.29% increase in the stock price over the next year, with targets ranging from $700 to $1,190.
Valuation presents a nuanced picture. Eli Lilly is currently trading at about 29 times forward earnings.
While elevated compared to traditional pharmaceutical companies, this multiple appears justified given the company’s exceptional growth trajectory and dominant position in the massive obesity market, which experts project could reach $150 billion annually by 2030.
Risk Factors to Consider
Despite the compelling investment thesis, several risks warrant attention:
Competitive Pressure: The GLP-1 market is intensifying with multiple competitors entering the space. Maintaining market share will require continued innovation and competitive pricing.
Execution Risk: Concerns exist regarding tirzepatide’s prescription trajectory falling short of expectations, coupled with the drug’s failure to demonstrate cardiac outcome benefits in non-diabetic obese patients.
Valuation Vulnerability: At current multiples, any disappointment in clinical trials or market adoption could trigger significant corrections.
Manufacturing Constraints: Despite capacity additions, meeting surging global demand while maintaining quality standards remains challenging.
Investment Verdict: Strong Buy
Eli Lilly presents one of the most compelling growth stories in large-cap pharmaceuticals. The combination of blockbuster products addressing massive unmet medical needs, strong pipeline execution, expanding market access through government agreements, and robust financial performance creates a powerful investment thesis.
The Trump administration pricing deal, rather than being dilutive, could prove transformative by dramatically expanding the addressable market.
With Medicare coverage beginning mid-2026 and oral formulations approaching approval, Lilly is positioned to capture significant additional market share.
For investors with appropriate time horizons and risk tolerance, current levels represent an attractive entry point despite premium valuations. The company’s 17.5% year-to-date gain may continue as the obesity treatment market matures and international expansion accelerates.
Also Read
Stock Market Dow Jones Today: Tech Turbulence Shakes Wall Street
Datadog Sees Shares Climb Nearly 4% on Exceptional Third-Quarter Performance